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The efficacy of whole-cell cancer vaccines have been investigated for more than 20 years in both preclinical models and in clinical trials in humans. [1] [2] [3] There are clear advantages of whole-cell vaccination over types of immunotherapy that target specific antigens. Multiple and unknown antigens may be targeted by both the innate and adaptive immune system. However, with few notable exceptions, immunization with whole-cell vaccines has not resulted in significant long-term therapeutic benefits. [4] [5] One possible explanation is that as only a small portion of cancer cell constituents are useful 'targets' for specific immune responses. 6 Figure 1 shows the approximate ratio of intracellular content to extracellular content. Intracellular content is sequestered within cells and therefore, less useful as antigens for vaccination, as only exposed, extracellular domains are accessible for humoral and cytotoxic immunity. Additionally, only a minority of cellular molecules can be considered useful targets for immune therapy because the vast majority of cellular constituents are not specific to cancer cells, including products of normal 'housekeeping' genes, carbohydrates, nucleic acids, and other contents that are ubiquitous among all mammalian cells. Not surprisingly, the immune responses in cancer patients are often insufficient to result in cancer rejection following cancer vaccine immunization. Therefore, vast improvements to cellular cancer vaccines are still required. 
Approach to improving vaccines
One possible and attractive approach for improving cellular cancer vaccines is to isolate essential targets of cancer cells and use them in vaccines instead of the whole cells. The meaningful targets for immune responses are mainly domains of surface-expressed proteins and glycoproteins that are accessible to antibodies and cytotoxic immune cells. These targets are also accessible to proteases and therefore, potentially can be isolated by proteolytic cleavage. The antigen profile obtained by proteolytic cleavage contains a comprehensive set of native antigens that can be used to direct immuno-therapeutics while minimizing the portion of ubiquitous molecules that are not useful targets. This approach to antigen isolation could potentially improve the efficiency with which cancer vaccines can be developed.
The 'bottleneck' in the approach
Improvement in developing cancer vaccines using this approach seems evident. Despite the fact that isolation of cell-surface molecules with proteases was described many years ago, 7-12 as well as use of cancer cells for vaccination, limitations in the applicability of such an approach were overcome only recently. Mainly, they concern protease impurity and cellular damage during manipulations.
Protease impurity
Trypsin (activity ~200 U/mg), at working concentration about 300 µg/ml, is widely used to cleave cell surface proteins. 7,13 Using 1 ml of such a trypsin solution can treat up to 5 × 10 6 cancer cells, which yield only 10-20 µg of cell-surface molecules. Thus, the quantity of protease is significantly greater than the quantity of collected cell-surface protein. Notably, the trypsin preparation contains numerous admixtures, including other proteases, differently degraded forms of trypsin, and autolysis products. Relatively more purified preparations of trypsin can be made, but they also generate numerous autolysis peptides during their actions.
14 Separating the trypsin admixtures from the population of collected cell-surface antigens is a complex task. These multistage and relatively complex approaches, which have been described in numerous sources, 7,10,15-23 only are used for separation and characterization of the limited number of separate antigens and are not applicable directly for vaccine production.
It is clear that only highly-purified trypsin should be used to produce preparation of cellsurface antigens directly from cancer cells. Trypsin concentrations of ~25 µg/ml, which correspond to trypsin activity > 3000 U/mg, can be used to generate cell-surface antigens with less protease impurity. It has recently been demonstrated that live cell treated with proteomics grade trypsin (5000 U/mg) resulted in solution of cell specific peptides. 24 Therefore, using trypsin of higher purity, e.g. modern trypsin preparations with activity up to 20000 U/mg, generates preparations of cell-surface antigens that contain negligible amounts of trypsin admixtures.
Cellular damage during manipulation
Animal cells are sensitive to fluid shearing in serum-free medium.
25-28 Therefore, any manipulation with cells in serum-free medium, which is required to obtain cleared cell surface antigens, leads to cell-membrane damage that releases intracellular content. Moreover, the protease itself may cause cell death during long treatments. Shown in Figure 1 , the quantity of cell surface antigens from 100 cancer cells is comparable to the quantity of intracellular molecules from just a single cell. Therefore, a critical aspect in preparing cellsurface antigens is to minimize the destruction of cells by fluid shearing during manipulation. Figure 2 shows that optimizing protocol conditions lead to observed death rate of < 0.1% of adenocarcinoma cells. Thus, we conclude that treating live cells with proteases allows collection of cell-surface antigens and prevents contamination by undesired intracellular content. For more shear-sensitive cell cultures, application of cyto-protectants significantly decreases the cell death rate during manipulations, 25 and may results in a cell antigen preparation of even greater purity. Figure 3 summarizes the influence both described conditions (protease impurity and cell death rate) on the purity of cell-surface antigen preparations. 
Proof-of-concept in vitro
To confirm that proteolytically-cleaved cell-surface antigens are sufficient for vaccination, their immunogenic properties were compared to that of whole cells. In a cytotoxicity assay, as an in vitro model of human anti-tumor therapies, human cytotoxic T-lymphocytes (CTLs) were incubated with target adenocarcinoma cells (MCF-7). CTLs were stimulated with dendritic cells (DCs) loaded with cell-surface antigens. DCs loaded with lysate of whole cancer cells were used for comparison. Generation of DCs 29 and cytotoxicyty assay were performed according to widely accepted protocols.
Visual inspection of target cancer cells in the cytotoxicity assay (Figures 4) revealed that that DCs loaded with cell-surface antigens induce cytotoxicity as effectively as DCs loaded with lysate. More precise calculation of dead target cells revealed that cell-surface antigens were ~20-30% more effective than lysate. Simultaneously, the whole-cell lysate contained 270 µg/mL protein, while the used solution of cell surface antigens contained 2 µg/mL.
Despite the solution of cell-surface antigens contained 2 orders-of-magnitude less protein than the lysate, it had the same ability to induce cytotoxic activity in CTLs. This is due to the necessary antigens being present in the solution of cell-surface antigens that is free of intracellular substances. This is a proof-of-concept, that the treatment of live cancer cells with proteases leads to the release of antigenic targets from cells that are sufficient to induce anti-cancer immune response in vitro. This leads to the possibility of using these preparations instead of cells as cancer vaccines. 
Future prospect of vaccines certification
Cultivated cell studies have indicated that cross-contamination between cell lines is widely prevalent and continues to be a major problem. [30] [31] [32] [33] [34] From the existing estimates, up to 36% of cell lines already appear to have a different origin than their initial cell lines.
34-35
Of the known authentication methods, short tandem repeat profiling (DNA fingerprinting) 35 is widely used and powerful method that provides an international reference standard for authentication of human cell lines. 36 However, in the case of cellular cancer vaccines, distinguishing surface antigens of target cancer cells and surface antigens of vaccines' cells is required.
Cultivated mammalian cells have a finite mitotic lifespan, [37] [38] [39] which is followed by cellular degeneration and modifications in cell-surface membranes. [40] [41] Most existing cell lines have been passaged extensively in vitro, and considerable variation and genomic instability have been observed in long-term cultures. [42] [43] Moreover, even cell lines that have been in culture for a relatively brief period of time, have displayed marked differences even from cultures derived from the same specimen. 44 This heterogeneity is pronounced at the genomic level and reflected in antigen expression. It might represent responses to selective pressures in vitro, 44 which lead to divergence of the cellular phenotypes over time.
In light of this, cultivated tumor cells intended for therapy must be analyzed for changes in their profile of surface antigens by comparing them with antigen profile of reference cancer cells. Current cancer vaccines which are already in clinical trials 45 have not passed such tests, partially, because there is no routine method of analysis. Intracellular content in these vaccines is prevalent and makes the composition of cell-surface antigens difficult to identify.
Cell surface antigens produced by our method are largely free of intracellular contents and suitable for direct mass spectrometric analysis. This is related to cell proteomic footprinting, a simple approach for authentication and characterization of cells with high speed and low sample cost ($15 per sample). 24 Through the direct comparison, compositions of cell-surface antigens with the proteomic footprints of the reference cells can be easily certificated for the proper use.
Safety of improved vaccines
A potential limitation with current cellbased vaccines is the difficulty associated with purifying cells from possible dangerous contaminants such as cell parasites, viruses, toxins and prions. Improving this aspect is essential for cell-based vaccines. [46] [47] Proteolytically-cleaved cell-surface antigens are peptides and glycopeptides. Therefore, simple ultrafiltration aimed to remove macromolecules and supramolecular structures renders antigens safe.
Conclusion
Further characterization of proteolytically-cleaved cell surface antigens, such as the choice of adjuvant and schedule, is required for vaccine development. However, the diversity of native tumor-associated antigens, low levels of undesirable antigens, and purity regarding dangerous intracellular agents, and possibility for certification demonstrates the potential for using cell-surface antigens as anticancer vaccine candidates.
